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Abstract 
 
Megalencephalic leukoencephalopathy with subcortical cysts (MLC), is a rare 
congenital and incurable leukodystrophy characterized by macrocephaly, subcortical 
fluid cysts and myelin vacuolation. The majority of MLC patients carry mutations in the 
MLC1 gene encoding a membrane protein named MLC1 that is highly expressed in 
brain astrocytes contacting blood vessels, ependyma and meninges. Although the 
neuropathological features of MLC disease, the molecular structure and the cellular 
localization of MLC1 suggest a possible involvement of this protein in astrocyte-
mediated osmoregulatory processes, the function of MLC1 is still unknown. 
Understanding the function of MLC1 protein whose mutations are the main cause of 
MLC is an essential step toward identification of disease mechanisms and development 
of effective therapies. 
During the course of this thesis project we generated new data on MLC1 expression, 
distribution and functional associated pathways in astrocytes that are deregulated by 
pathological mutations, paving the way for the identification of the specific MLC1 
function. We found that: i) endogenous MLC1 protein is expressed in cultured 
astrocytes, particularly in the plasma membrane where it interacts with caveolin-1 and 
proteins of the dystrophin/dystroglycan complex (DCG), and also in intracellular 
organelles and endoplasmic reticulum (Lanciotti et al., 2010); ii) MLC1 undergoes 
endolysosomal trafficking and, most of the missense mutations found in patients 
hamper MLC1 intracellular trafficking  and localization at the plasma membrane 
(Lanciotti et al., 2010, 2012); iii) MLC1 directly binds the beta-1 subunit of the Na, K-
ATPase enzyme and is part of a multiprotein complex that includes the inward 
rectifying potassium channel 4.1 (Kir4.1), caveolin-1 and syntrophin, and is involved in 
astrocyte response to hyposmotic stress (Brignone et al., 2011). Moreover, we generated 
a human pathological model based on astrocytoma cell lines overexpressing wild-type 
(WT) MLC1 or MLC1 carrying pathological mutations. Using this new MLC disease 
model we found that WT, but not mutated MLC1, functionally interacts with the 
transient receptor potential cation channel-4 (TRPV4) to activate swelling-induced 
calcium influx in astrocytes during hyposmotic stress (Lanciotti et al, 2012). These 
findings, together with a recent study showing defects in a chloride current in patient-
derived lymphoblast cell lines subjected to hyposmosis (Ridder et al, 2011), represent 
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the first evidence that the MLC1 protein is involved in the molecular pathways 
regulating astrocyte response to osmotic changes. 
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Introduction 
 
1. Leukoencephalopathies 
 
The term leukoencephalopathy is a broad term used to classify the heterogeneous group 
of rare genetic diseases that cause childhood-onset cerebral white matter disorders, with 
either primary or secondary changes in myelin development or maintenance (Blumkin 
et al., 2009). Clinically, the typical child-disease with white matter abnormalities is 
characterized by the onset of symptoms within the first year of life, most often 
presenting as general developmental psychomotor delay and hypotonia. Later-appearing 
signs are spasticity and ataxia and serious ophthalmological abnormalities, as a rule 
severe learning and motor disabilities. However, these symptoms are not general and 
some variations of them, such as age at onset, severity of mental retardation and motor 
impairment, as well as the extension of white matter alterations, are also noted within 
this heterogeneous group of disorders (Kristjansdottir et al., 2000).  
The diagnostics of cerebral white matter disorders was revolutionized by the advent of 
magnetic resonance imaging (MRI) in the late 1980s. MRI is very sensitive in showing 
macroscopic structural changes in the white matter: first, it can be used to show gross 
morphology and the involvement of different brain structures or tissues; second, to 
monitor the progression of the disease or the response to therapy; finally, the pattern of 
abnormal MRI findings, which can be typical for a particular disease type, can aid in the 
diagnosis, as summarized in Table I (adapted from Di Rocco et al., 2004). In fact, by the 
identification of specific “MRI pattern recognition” (van der Knaap et al., 1995), some 
new genetic diseases, such as megancephalic leukoencephalopathy with subcortical 
cysts (MLC) and vanishing white matter/childhood ataxia with central hypomyelination 
(CACH), have recently been identified (Di Rocco et al., 2004). So, MRI has provided a 
powerful tool for investigating the cerebral white matter in living individuals. Its 
increased use for the diagnosis of children with neurological impairment has expanded 
our knowledge about genetic disorders affecting white matter, contributing to the 
identification, localization and characterization of underlying white matter 
abnormalities in affected patients. 
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1.1 Leukoencephalopathies' classification. 
The term leukoencephalopathy is applied to all white matter diseases of known and 
unknown origin. Although magnetic resonance imaging (MRI) has greatly improved the 
diagnosis of leukoencephalopathies, most of these diseases are still difficult to be 
recognised and almost 50% of them are of unknown cause. The white matter 
abnormality may appear similar in different forms of leukoencephalopathy so that in 
most cases, further investigations such as magnetic resonance spectroscopy, tissue 
biopsies, enzyme studies and molecular DNA analyses are needed to pinpoint a more 
accurate diagnosis. A specific diagnosis allows the physician to give prognostic 
information, monitor for known complications and ultimately may allow disease-
specific therapeutic strategies. Therefore a specific protocol for studying and 
categorizing these patients is crucial. 
Different ways to classify leukoencephalopathies are available, based on either 
pathological, biochemical, genetic data, or combined clinical and 
histological/biochemical criteria.  
The well-defined leukoencephalopathies can be divided into the following categories on 
the basis of the myelin damage typology: (1) dysmyelinating, showing abnormally 
formed myelin; (2) hypomyelinating, with decreased myelin production; and (3) 
spongiform,  with cystic degeneration of myelin (Kaye, 2001). 
A classification based on the biochemical defect observed can also be used to classify 
leukoencephalopathies and it encompasses (1) lipid disorders, (2) myelin protein 
disorders, (3) organic acids disorders, (4) defects of energy metabolism (associated with 
lactic acidosis), (5) other causes, and (6) unknown causes (Table II) (Kaye, 2001). 
By using an integrated MRI and pathophysiological approach, as proposed by van der 
Knaap (2001), pediatric white matter disorders can be distinguished into well-defined 
leukoencephalopathies, and undefined leukoencephalopathies.  
The second category,  that represents up to 50% of leukoencephalopathies in childhood, 
requires a multidisciplinar approach (clinical, neuroradiological and 
electrophysiological analysis) in order to define novel homogeneous subgroups of 
patients for identifying their molecular or biochemical defects (Di Rocco et al., 2004; 
Blumkin et al., 2009). These classifications will certainly change as the molecular 
mechanisms for more leukoencephalopathies become elucidated.  
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Table I 
Classification of the most 
diffuseleucoencephalopathy 
(adapted from Di Rocco et al., 2004). 
Disorder Classification Genetic defect MRI findings 
Pelizaeus–
Merzbacher disease 
Hypomyelinating 
Mutations in the 
proteolipid protein 1 
(PLP1) gene 
Arrested myelination (however normal for that stage); high 
signal intensity on T2-weighted images within unmyelinated 
WM; reduced WM volume, enlarged ventricular system, thin 
corpus callosum; brain atrophy mainly in the brainstem and 
cerebellum 
Metachromatic 
leukodystrophy 
Dysmyelinating 
Mutations in the 
arylsulfatase A (ARSA) 
gene 
Symmetrical periventricular WM abnormalities; early 
sparing of the arcuate fibers; involvement of the corpus 
callosum; brain atrophy in the advanced stages of disease 
X-linked 
adrenoleukodystrophy 
Dysmyelinating 
Mutations in the ATP-
binding cassette 
transporters (ABCD1) 
gene 
Extensive WM lesions in the occipital regions with 
involvement of the splenium of the corpus callosum and 
sparing of the occipital arcuate fibers; early involvement of 
the pyramidal and occipito-parieto-temporo-pontine tracts 
are involved early 
Globoid cell 
leukodystrophy 
Dysmyelinating 
Mutations in the 
galactosylceramidase  
(GALC) gene 
Demyelination of the deep WM, progressively involving the 
subcortical white matter. Calcifications within the thalami, 
basal ganglia, and corona  adiate shown by CT scan 
Alexander disease 
Spongiform with 
cystic 
degeneration 
Mutations in the glial 
fibrillary acid proteic 
(GFAP) gene 
Extensively abnormalWM with swollen appearance and 
cavitations, namely in the frontal lobes; abnormalities of 
basal ganglia, thalami, and brainstem; positive enhancement 
Canavan disease Spongiform 
Mutations in the 
aspartoacylase (ASPA) 
gene 
Subcortical cerebral and cerebellar WM are predominately 
involved with a swollen appearance; later involvement of the 
central WM; bilateral involvement of the globus pallidus and 
of the thalamus with sparing of the caudate nucleus and 
putamen; cerebral and cerebellar atrophy; marked increased 
NAA peak on MR spectroscopy 
Megalencephalic 
leukoencepahlopathy 
with subcortical cysts 
Spongiform 
Mutations in the MLC1 
or HEPACAM gene* 
Diffusely abnormal, swollen cerebral WM with subcortical 
cysts in the anterior-temporal regions; sparing of the central 
WM; normal gray matter structures 
Vanishing white 
matter (VWM or 
CACH**) 
Spongiform 
Mutations in the 
Eukariotic Initiation 
Factor 2 (EIF-2B) gene 
Symmetric, diffuse involvement of the cerebral hemispheric 
WM, including the central tegmental tracts; cystic 
degeneration of WM that is replaced by CSF; cerebellar 
atrophy 
WM, white matter.    
* MLC1: Megalencephalic leukoencepahlopathy with subcortical cysts; HEPACAM: hepatic and glial cell adhesion molecule, 
** CACH: Childhood ataxia with central nervous system hypomyelination 
 
 
 
Table II. Biochemical classification of the leukoencephalopathies (adapted 
from Kaye, 2001) 
Lipid  
Adrenoleukodystrophy 
Globoid cell leukodystrophy 
Metachromatic leukodystrophy 
Sjo¨gren-Larsson syndrome 
Cerebrotendinous xanthomatoses 
Myelin Proteins Pelizaeus-Merzbacher disease 
Myelin basicprotein deficiency 
Organic Acid Disorders  Canavan’s disease 
Energy Defects  
Progressive cavitating leukoencephalopathy 
Type IV glycogenstorage disease questa 
Other Causes 
CADASIL(Cerebral Autosomal Dominant 
arteriopathy with subcortical infarcts and 
leukoencephalopathy) 
Merosin deficiency 
 Unknown biochemical mechanism 
Alexander’s disease 
CACH (vanishing white matter) 
VLE (vacuolating leukoencephalopathy) 
Aicardi-Goutieres syndrome 
MLC (Megalencephalic 
leukoencepahlopathy with subcortical cysts) 
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1.2  White matter and  Myelin: pathological targets in leukoencephalopathies 
The central nervous system is composed of two different types of tissue: the grey matter 
and the white matter. The grey matter, which has a pinkish-grey color in the living 
brain, contains the cell bodies, dendrites and axon terminals of neurons; while the white 
matter appears pinkish-white to the naked eye because myelin is composed largely of 
lipid tissue veined with capillaries. Its white color is due to its usual preservation in 
formaldehyde. The white tissue is mainly composed of nerve cell processes, or axons, 
which connect various grey matter areas of the brain and carry nerve impulses and are 
insulated with the layer of proteic and fatty substance named myelin. On a dry weight 
basis, 40-50% of white matter is myelin, which gives white matter its color and is 
responsible for the fast nerve conduction (Baumann and Pham-Dinh, 2001). The white 
matter tissue is the main target for the brain damages in leukoencephalopathies whose 
genetic defects can lead to delayed and disturbed myelin formation, progressive 
demyelination or myelin structural alterations, like cystic degeneration, either with  
myelin loss or  without myelin loss.  
In the well-defined leukoencephalopathies pathological damages can be due directly to 
genetic alterations of myelin specific structural proteins or also secondary due to 
dysfunction of neurons or of non neuronal types of cells named glial cells.  
Indeed all neural tissues, both white and grey matter, contain two major classes of cells: 
nerve cells (neurons) and glial cells (Figure 1.1). Glial cells constitute the large majority 
of cells in the nervous system and are necessary for neuronal development and  myelin 
formation and for the correct functionality of mature neurons. Moreover they account 
for the maintenance of the general brain homeostasis conditions and for immune 
response. Glial cells can be divided into two major classes: macroglia which encompass 
ependymal cells, astrocytes and oligodendrocytes and microglia which represent the 
brain resident macrophages.  
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Fig.1.1 Cellular Organization in Neural Tissue. Neural tissue contains two 
distinct cell types: nerve cells, or neurons, and supporting cells, or neuroglia. 
Neurons are responsible for the transfer and processing of information in the 
nervous system, while neuroglia for isolating the neurons, for trophic and 
structural support to neurons and for immune response in the brain. 
 
1.2.1  The myelin forming cells and myelin structure  
The myelin sheath is crucial to propagate electrical signals more efficiently (Kandel 
E.R. et al., 2000). In the CNS, myelin is formed by differentiation of the plasma 
membrane of a glial cell component: the oligodendrocytes. Oligodendrocyte damages 
and alteration of their functionality are often found as primary pathogenic causes for 
leukoencephalopathies. Moreover, the other glial component astrocytes and many 
soluble factors (Di Rocco et al., 2004) are essential for the correct myelin development 
and maintenance. Recently mutations in astrocyte specific proteins and astrocyte 
dysfunctions have been recognised as the leading cause of some cystic leukodystrophies 
(Brenner et al.,  2001) among which MLC disease (van der Knaap et al., 2012). For 
these reasons the main structural and functional features of these two types of glial cells 
will be discussed in the next sections.   
 
1.2.2 Oligodendrocytes  
The term oligodendroglia was introduced by Rio Hortega to describe those neuroglial 
cells that show few processes in material stained by metallic impregnation techniques. 
Oligodendrocytes are cells highly specialized to myelinate central nervous system 
axons. An oligodendrocyte extends many processes, each of which contacts and 
repeatedly envelopes a stretch of axon and forms a double membrane structure called 
the mesaxon, which elongates and spirals around the axon in concentric layers 
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(Baumann and Pham-Dinh, 2001), with subsequent condensation of this multispiral 
membrane-forming myelin. On the same axon, adjacent myelin segments are formed by 
different oligodendrocytes. The number of processes that form myelin sheaths from a 
single oligodendrocyte varies according to the area of the CNS and possibly the species, 
from 40 in the optic nerve of the rat to 1 in the spinal cord of the cat (Baumann and 
Pham-Dinh, 2001 and references therein). Myelination by oligodendrocytes begins 
when axons to be myelinated acquire a diameter of approximately 1 μm (Morell P., 
1984). A small amount of myelin is formed in humans before birth, but most myelin 
develops after birth, during the first two years of life. Myelination of the cerebral 
hemispheric white matter continues until adolescence (van der Knaap M. S. and Valk J., 
2005). Its unique composition and its unique segmental structure responsible for the 
saltatory conduction of nerve impulses allows the myelin sheath to support the fast 
nerve conduction in the thin fibers in the vertebrate system. It is present both in the 
central and in the peripheral nervous system (PNS), but the myelin-forming cells and 
composition of myelin differ between these two systems. Schwann cells are the 
supporting cells of the peripherical nervous system; like oligodendrocytes Schwann 
cells wrap themselves around nerve axons, but the difference is that a single Schwann 
cell makes up a single segment of an axon's myelin sheath.  The oligodendrocyte is not 
alone a myelin forming cell, but there are also satellite oligodendrocytes that may not be 
directly connected to the myelin sheath. Satellite oligodendrocytes are perineuronal and 
may serve to regulate the microenvironment around neurons (Ludwin, 1997). 
 
         1.2.3 Myelin: structure and composition  
The insulating properties of the myelin sheath, which favours rapid nerve conduction 
velocity, are largely due to its structure, its thickness, its low water content, and its 
richness in lipids (Baumann and Pham-Dinh, 2001).  
Each myelin sheath is composed of multiple segments of myelin, which are modified 
extensions of oligodendroglial cell process, surrouding a portion of an axon in a spiral 
fashion (Figure 1.2) (Sherman and Brophy, 2005). 
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Fig.1.2 The relationship between an oligodendrocyte and myelinated nerve fiber 
in the CNS. An oligodendrocyte extends and surrounds neighbouring axons and 
the myelinating process are composed in a spiral fashion. At node of Ranvier 
myelination causes clustering of voltage-gated sodium channels (adapted from 
Sherman and Brophy, 2005).    
 
A structural feature that characterizes myelin sheath is its periodic structure, with 
alternating concentric electrondense and light layers: the major dense line (dark layer)  
is formed by the close apposition of the internal faces followed by the extrusion of the 
cytoplasm of the expanding myelinating processes of the oligodendrocyte; the 
apposition of the external faces of the membrane of the myelinating cell forms the 
intraperiodic lines (or minor dense lines) (Figure 1.3). The concentric layers that forms 
a sheath around the axon are called lamellae. The several sections of myelin sheaths are 
separated from each other by small unmyelinated segments in which the bare axon is 
exposed to the interstitial space. These segments, called nodes of Ranvier, contain a 
cluster of voltage-gated sodium channels (Figure 1.2). The periodicity of the lamellae is 
12 nm and each myelin sheath segment or internode appears to be 150–200 µm in 
length. When the axon membrane is excitated, the electrical impulse cannot flow 
through the high resistance myelin sheath, but flows out through and depolarizes the 
axonal membrane at the next node. This salutatory conduction allows the fast nerve 
conduction at a lower energy cost that is crucial for functional integration of the CNS. 
Common in the PNS, but rare in the CNS are the Schmidt-Lanterman clefts (also called 
Schmidt-Lanterman incisures), regions within compact myelin in which the cytoplasmic 
faces of the enveloping myelin sheath are not tightly juxtaposed to form the major dense 
line, and include cytoplasm from the cell responsible for making the myelin. Myelin is 
less compacted at the inner and outer end of the spiral, forming inner and outer loops 
that retain small amounts of oligodendrocyte cytoplasm near the node of Ranvier. These 
little expanded loops are arranged on a roughly regular and symmetric pattern on each 
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side of the node, forming a sequence of loops, termed the paranodal region or paranode, 
which makes contact with the axon. 
The importance of myelin in human development is highlighted by its involvement in 
an array of different neurological diseases such as leukodystrophies and multiple 
sclerosis (MS) in the CNS and peripheral neuropathies in the PNS (Sherman and 
Brophy, 2005). 
 
 
                       
                              
 
Fig.1.3 Myelinating glial cells, myelin structure, and composition in the PNS and 
in the CNS. In the PNS, the myelinating Schwann cell myelinates only one 
segment of axon, whereas in the CNS the oligodendrocyte is able to myelinate 
several axons. The compact myelin is formed by the apposition of the external 
faces of the membrane of the myelinating cell, forming the “double intraperiodic 
line”; the apposition of the internal faces followed by the extrusion of the 
cytoplasm, form the “major dense line” (adapted from Baumann and Pham-Dinh, 
2001). 
 
Compared with other membranes, the composition of myelin is unique, with low water 
content (40%) and a very high percentage of lipids compared with the plasma 
membranes of most eukaryotic cells. On a dry weight basis, myelin contains 70% lipids 
and 30% proteins, all formed in the oligodendrocytes. This lipid-to-protein ratio is very 
peculiar to the myelin membrane, while it is generally the reverse in other cellular 
membranes (Baumann and Pham-Dinh, 2001).  
The lipid layers are composed of cholesterol, phospholipids, glycolipids, and 
hydrocarbon chains. Glycolipid (galactocerebroside and sulfatide) and cholesterol are in 
the outer layer of the membrane, exposed to the extracellular space. Phospholipids are 
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hydrophobic and are located in the inner (cytoplasm) side of membrane. The area 
between outer and inner membrane layers is composed primarily of hydrocarbon chains 
(long chain fatty acids). 
Most myelin proteins are unique to myelin. Each protein is localized at a specific site in 
the myelin membrane, reflecting its function. The two major structural proteins of 
myelin are proteolipid protein (PLP) and myelin basic protein (MBP), accounting for 
50% and 30% of the total protein,  respectively. Both proteins play a role in maintaining 
stability and periodic structure of myelin: MBP is necessary for myelin compaction, 
adhering the cytoplasmic leaflets of the myelin membrane, while PLP (and its isoform 
DM20) stabilizes the intraperiod line of the membrane (Campagnoni and Skoff, 2001). 
However the pathobiology of myelin mutants reveal novel biological functions of the 
MBP and PLP genes The non-classic MBP gene products appear to be components of 
transcriptional complexes in the nucleus, and they also may be involved in signaling 
pathways in T-cells and in neural cells. The non-classic PLP/DM20 gene products 
appear to be components of intracellular transport vesicles in oligodendrocytes. There is 
evidence for other functions of the classic PLP/DM20 proteins, including a role in 
neural cell death mechanisms, autocrine and paracrine regulation of oligodendrocytes 
and neurons, intracellular transport and oligodendrocyte migration (Campagnoni and 
Skoff, 2001). In addition, a few other myelin proteins have been identified: myelin-
associated glycoprotein (MAG), which is localized in the periaxonal myelin membrane 
and is the mediator of the axonal-glial contacts, essential for the initiation of 
myelination; myelin-oligodendrocyte glycoprotein (MOG), which is localized on the 
outside surface of the myelin sheaths and it is thought to transmit signals from the 
extracellular environment and to be an important target in autoimmune demyelinating 
diseases (Quarles, 2002.); and the 2,3-cyclic nucleotide 3-phosphodiesterase (CNP), 
only found in non compact parts of myelin (e.g. in paranodal loops), that seems to be 
not involved in myelin assembly but essential for axonal survival (Lappe-Siefke et al., 
2003; Di Rocco et al., 2004). 
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1.3 Astrocytes 
Among the central nervous system (CNS) glial population, astrocytes are the most 
numerous components and account for a large portion of total brain volume (20-50%). 
Their name was coined by Michael von Lenhossek who called "astrocytes" the star-
shaped cells found in the CNS. Generally astrocytes are divided into two types, fibrous 
and protoplasmic, similar in function but distinct in morphology and distribution 
(Kandel E.R. et al., 2000). The fibrous astrocytes contain many filaments and are found 
in the white matter areas. Protoplasmic astrocytes are found in gray matter and are 
characterized by many short, thick and highly branched processes associated with nerve 
cell bodies, dendrites and particularly synapses (Kandel E.R. et al., 2000). Both types of 
astrocytes form gap junctions between distal processes of neighboring astrocytes 
(Wanga and Bordey, 2008; Sofroniew and Vinters, 2010).  Originally thought as “brain 
glue”, it has become clear in recent years that astrocytes are important for virtually all 
brain functions (Ransom B. et al., 2003). Due to their strategic location and structural 
and biochemical features astrocytes are the cells optimized by the natural selection to 
sense their surroundings and dynamically respond to changes in the microenvironment. 
They have infact several critical functions including promoting neuronal maturation, 
synapse formation, neuronal survival during development, regulating angiogenesis, and 
maintaining a viable microenvironment for neurons (Wanga and Bordey, 2008). Either 
protoplasmic and fibrous astrocytes are reported to contact and have bidirectional 
relationships with blood-brain barrier (BBB) components with whom they participate to 
BBB formation and maintenance and where they regulate the exchanges between 
intraparenchimal milieu and the external environment. Astrocytes also contact meninges 
and ependymal layer lining the ventricles contributing to support brain cerebrospinal 
fluid barrier structures (Li et al., 2010; Mack AF and Wolburg H, 2012). Briefly, they 
control ion and fluid homeostasis (uptake functions), support neuron development and 
functions (trophic and metabolic functions), blood brain barrier formation and 
maintenance and react to different types of pathogenic insult in the brain. Moreover they 
also support oligodendrocyte functions and myelin formation. Due to their multitasking 
activities astrocytes are involved almost all the diseases of the CNS. In the following 
sections astrocyte functions will be described in detail  (Figure 1.4)  
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Fig.1.4.The well-established functions of astrocytes. 
Astrocytes have several homeostatic functions 
maintaining a viable nervous system environment for 
neurons. These functions include: (1) providing 
metabolic support for neurons, (2) taking up K+ and 
neurotransmitters (3) Synaptogenesis, angiogenesis 
and brain blood barrier formation and maintenance 
(adapted from Wanga and Bordey, 2008). 
 
 
 
    
 
a) Metabolic function. 
Astrocytes are uniquely poised to provide a local metabolic support for neurons and the 
role of astrocytes in the supply of energy substrates to neurons is one of their oldest 
known functions. Astrocytes are located at a strategic position between blood capillaries 
and neurons: astrocyte processes, on the one hand, project toward blood vessels that 
terminate into structures called endfeet, which almost entirely cover the blood vessel 
walls, and on the other hand contact neuronal perikarya, axons (at nodes of Ranvier), 
and synapses (Figure 1.1). Magistretti and colleagues proposed an important hypothesis 
termed the astrocyte-neuron lactate shuttle hypothesis (ANLSH) in which, in response 
to glutamatergic neuronal activity, glucose enters the CNS via the astrocytic processes 
and is there converted, by aerobic glycolysis, to glycogen and lactate, which then serve 
as the principal food for neurons (Magistretti et al.,1993; Pellerin and Magistretti, 1994; 
Voutsinos-Porche et al., 2003). This activity-dependent mechanism involves Na+-
coupled glutamate uptake in astrocytes and activation of the Na+/K+ ATPase, which 
triggers glucose uptake from the blood and its glycolytic processing, resulting in the 
release of lactate from astrocytes (Figure 1.5a) (Giaume et al., 2010). Moreover 
astrocytes are the principal storage sites of glycogen granules in the CNS, which 
utilization can sustain neuronal activity during hypoglycaemia and periods of high 
neuronal activity. Even when glutamate spillover stimulates a distant astrocyte closed to 
a blood vessel (dark blue in Figure 1.5b), glucose and metabolites produced after 
glucose uptake from the blood permeate gap junction channels and reach adjacent 
astrocytes that are in contact with the active neurons  providing them with energy 
substrates (light blue in Figure 1.5b). 
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Fig.1.5 Astroglial metabolic networks sustain neuronal activity. a) The mechanism 
underlying glutamate-induced glycolysis during glutamatergic synaptic activity. b) The 
contribution of the astrocyte network to the glucose–lactate shuttle shown in a) (adapted 
from Giaume et al., 2010). 
 
b) Uptake function: taking up potassium ion (K+ ) and neurotransmitters  
Astrocytes are the main cellular element involved in the mainteinance of extracellular 
homeostasis in the CNS. Numerous transport systems expressed in astroglial 
membranes provide the control over the concentrations of ions, neurotransmitters, 
neuromodulators, metabolites and other active molecules in the interstitium.  
During normal neuronal activity, neurotransmission leads to the build up of K+  ions 
into the extracellular space, and if not corrected, results in neuronal depolarization, 
hyperexcitability, and seizures. On the base of a mechanism termed spatial buffering¸ 
astrocytes take up the excess of extracellular K+ ions, distribute them through the gap 
junction-coupled astrocytic syncytium and extrude the ions at sites of low extracellular 
K+ level. To achieve spatial K+ buffering, astrocytes are poised with passive and active 
uptake capabilities, via channels (predominantly by inwardly rectifying K+ channels 
(Kir)) and co-transporters, and via Na+/K+ ATPases, respectively (Wanga and Bordey, 
2008). Astrocyte processes at synapses also play essential roles in transmitter 
homeostasis by expressing high levels of transporters for neurotransmitters such as 
glutamate, GABA and glycine that serve to clear the neurotransmitters from the 
synaptic space. Glutamate is the major excitatory transmitter of the brain and one of the 
most important tasks of astrocytes is to maintain a low concentration of extracellular 
glutamate. Glutamate uptake by astrocytes terminates its eff ects as a neurotransmitter, 
prevents extracellular glutamate levels from reaching excitotoxic levels, and leads to 
futher utilization as a metabolic substrate. To this aim astrocytic processes surrounding 
synapses take up glutamate through transport proteins, particularly EAAT1 and EAAT2 
(Huang et al., 2004). After the uptake into astrocytes, the transmitters are converted by 
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enzymes into precursors and recycled back to synapses for reconversion into active 
transmitters (Sofroniew and Vinters, 2010). 
 
c) Astrocyte in the control of ion and water exchange and cell volume regulation  
Astrocytes have long been recognized as the chief regulator of water homeostasis in the 
brain and contribute to a stable osmotic environment in several ways (Del Zoppo G. J. 
and Hallenbeck J. M., 2000). The next paragraph describes four examples of how these 
glial cells, via the detection of osmotic changes, are capable of initiating an osmo-
regulatory process in the brain. The relative contribution of these mechanisms varies 
depending on a number of factors including the density, expression pattern and water 
fluxing capacity of the individual channels and co-transporters (Agre P. et al., 2004). 
The first osmo-regulatory process in which astrocytes are involved is the previously 
mentioned potassium spatial buffering that is primarily mediated by Kir4.1 channel. In 
this way astrocytes maintain extracellular potassium optimal for neuronal signaling. The 
net ion gain results in osmotic water uptake via AQP4 and causes a slight cell swelling 
and subsequent water clearance via astrocytic endfeet at the blood-brain barrier 
(Nagelhus E.A. et al., 2004). The second example is neurotransmitter recycling, which 
can also lead to local changes in ions and water.  Glutamate transport is sodium-
dependent and accompanied by net uptake of ions and water, again contributing to water 
clearance via astrocytic endfeet at the blood-brain barrier (Nagelhus E.A. et al., 2004). 
The two previously described examples concern activity-dependent water flux. This 
activity dependent water influx is superimposed on a constitutive efflux of a substantial 
amount of water derived from the metabolic breakdown of glucose, the main energy 
substrate of the brain (Amiry-Moghaddam M. and Ottersen O. P., 2003). The last osmo-
regulatory process is called regulatory volume decrease (RVD). RVD is a corrective 
process leading to cell volume recovery after rapid cell swelling as a response to 
decreased external osmolarity. RVD is caused by an efflux of chloride, potassium and 
organic osmolytes, such as amino acids plus their derivates (taurine, proline, alanine) 
(Strange K. et al.,1996). The chloride channels activated by cell swelling  are called 
volume-regulated anion channels (VRACs). 
 
d) Synaptic support  
Recent findings have shown that astrocytes are required for synaptogenesis and for  the 
structural maintenance and proper functioning of synapses. Indeed one of the most 
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important role of astrocytes is to optimize the functionality of synapses by maintaining 
the interstitial space homeostasis by a tight control of fluid, ion, pH and transmitter 
homeostasis at the synaptic clefts  as described above (Kimelberg and Nedergaard 
2011). Clear evidence has accumulated indicating that the CNS synapse is composed of 
three elements: the presynapse, the postsynaptic membrane and the nearby astrocyte 
that, with its processes, make intimate contacts with the neuronal synaptic structures. 
The existence of a bidirectional communication between astrocytes and neurons was 
termed “tripartite synapse”  (Faissner et al., 2010). Inded astrocytes release factors 
including extracellular matrix (ECM) proteins, cytokines,  metabolites such as 
cholesterol influencing synaptic development nd functioning and interact with neurons 
via cell–cell and cell–ECM based adhesion mechanisms. Increasing experimental 
evidence demonstrated that astrocytes actively participate in modulating synaptic 
activity also by releasing neurotransmitters (so-called gliotransmitters). Several 
mechanisms of transmitter release from astrocytes have been proposed.  Astrocytes 
react to synaptically released neurotransmitters with intracellular calcium ([Ca(2+)]) 
elevations, which in turn generates the regulated secretion of astrocyte-derived 
gliotransmitters, mainly glutamate and ATP, but also GABA and D-serine , mainly 
through a process of Ca dependent vesicular release (review by Zorec et al., 2012). 
Other soluble factors produced by astrocytes  that can influence synaptic activity are 
neurosteroids, growth factors and cytochines that can be released by astrocytes in 
different areas of the brain or in pathological conditions.  
Then, the concept of the tripartite synapse proposes that astrocytes constitute an integral 
part of the synapse, as cellular elements involved in the processing, transfer and storage 
of information by the nervous system.  
 
 
1.3.1 Astrocytes relationship with oligodendrocyte and myelin 
The astrocyte-mediated growth factor production, which promote neuronal survival in 
normal (Dreyfus et al., 1999) and injured brain (Schwartz et al., 1996), is also essential 
for survival of oligodendrocytes, the myelin forming cells. The importance of astrocytes 
as modulators of oligodendrocyte proliferation and differentiation in vitro was first 
recognized more than 20 years ago when astrocytes were found a major source of 
proliferating and differentiating factors in particular PDGFα and FGF2 for 
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oligodendrocyte progenitors (Bögler et al., 1990; Noble and Murray, 1984; Noble et al.,  
1988; Richardson et al.,  1988). 
Additional contribute to myelin maintenance is given by astrocytes through gap junction 
communication as demonstrated by studies on mice double-deficient for connexins 
forming  heterotypic interactions between astrocytes and oligodendrocytes which show 
extensive white matter vacuolation and myelin defects (Tress et al., 2011).   
Moreover via gap junctions astrocytes are structurally and functionally interconnected 
into a highly organized network which allows them to communicate and coordinate 
their activities like a syncitium (a multinucleated mass of cytoplasm resulting from the 
fusion of cells) by the transfer of calcium waves, small molecules including second 
messengers and ions. Into a lesser extent astrocytes through gap junctional 
communication can also modulate the activity of adjacent cells like oligodendrocytes 
and neurons (Thesis M and Giaume C, 2012). 
 
1.3.2   Astrocytes and brain pathology 
Considering the key role played by astrocytes in the maintenance of brain homeostasis, 
the strong metabolic cooperations between astrocytes and neurons and their direct and 
indirect influence on myelin formation and oligodendrocyte survival it is conceivable 
that astrocytic dysfunctions and incorrect neuron-astrocyte or oligodendrocyte-astrocyte 
interactions may be involved in CNS and neuronal damaging. 
According with these observations it is not surprisingly that the number of CNS 
inflammatory diseases in which the contribute of astrocytes to neurodegeneration 
became pathological important is continuously updating. Moreover due to astrocytic 
influence on oligodendrocytes and myelin formation astrocyte dysfunction can 
participate to demyelinating disease. 
Evidence is emerging that alterations in astrocyte functionality plays a crucial role in the 
pathogenesis of different types of brain disorders including neurodegenerative diseases 
as demonstrated by the genetic leukodystrophy, Alexander disease. in which myelin 
degeneration is caused by mutations in the gene encoding the astrocytic specific glial 
fibrillary acidic protein GFAP. Along with Alexander disease, Megalencephalic 
leukoencephalopathy with subcortical cysts (MLC) and Vanishing white matter disease 
(VWM/CACH) are other two examples of diseases in which myelin degeneration 
occurs as a secondary defect following a primary astrocyte dysfunction. 
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1.4 Ependymal cells 
Other glial cells potentially involved in brain damages observed in some 
leukoencephalopathies are the ependymal cells (Ambrosini, 2008). Ependymal cells are 
the epithelial cells that line the central canal system of the brain and spinal cord. 
Recently, several functions for these cells have been suggested, including a barrier for 
filtration of brain molecules, protection of the brain from potentially harmful substances 
from the cerebrospinal fluid (CSF), movement of cellular debris, and optimization of 
the dispersion of neural messengers in the CSF (Spassky N. et al., 2005). Further 
investigation will be needed to understand the role of these cells in the pathogenesis of 
leukoencephalopathies. 
 
1.5 Microglia  
The involvement of inflammatory processes and immune response in some  
leukoencephalopthies  have been recently demonstrated (Luzi P et al., 2009) and 
activation of CNS resident macrophages has been found. 
The CNS resident macrophages are microglial cells. These cells  are a collection of 
phagocytic cells that arise from macrophages outside mettere bene formattazionethe 
nervous system and are physiologically and embryologically unrelated to the other 
cell types of the nervous system. These cells normally exist in the CNS in small 
numbers, but they multiply and become activated during infection, injury, and seizures. 
Activated microglia have processes that are stouter and more branched than those of 
inactivated cells, and they express a range of antigens, suggesting that they may serve as 
the major antigen-presenting cell in the CNS (Kandel E.R. et al., 2000). 
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2. Megalencephalic leukoencephalopathy with subcortical 
cysts (MLC). 
Megalencephalic leukoencephalopathy with subcortical cysts (MLC, OMIM 604004) is 
a rare congenital and incurable leukodystrophy characterized by early–onset 
macrocephaly, subcortical cysts and swollen appearance of the white matter which was 
first described by Van der Knaap et al. (1995).  
 
2.1 Clinical phenotype 
MLC patients manifest: 
 Macrocephaly. Patients develop macrocephaly during the first year of life, but 
some children are born with it. 
 Slow deterioration of motor functions occurs with cerebellar ataxia and mild 
spasticity, which eventually leads to the inability to walk. 
 Cognitive deterioration is usually late and mild. 
 Epiletic Seizures. Almost all patients have epileptic seizures from early on, but 
are usually easily controlled with medication. 
The disease is also characterized by a slowly progressive clinical course that can be 
worsened by minor stress, particularly minor head trauma and common viral infections. 
(van der Knaap et al., 1995; Goutieres et al., 1996; Singhal et al., 1996; Topçu et al., 
1998; Ben-Zeev et al., 2002).  
 
2.2 MRI and histopathological analysis 
Magnetic resonance imaging analysis of the brain indicates diffuse white matter 
swelling and invariant bilateral subcortical cysts, in the anterior-temporal and often in 
the fronto-parietal regions (Figure 2.1 B), two main features characterizing MLC 
disease (Van der Knaap et al., 1995, 1996). The cerebral white matter is diffusely 
abnormal in signal and slightly swollen; the occipital white matter often looks a bit less 
abnormal and less swollen. Central white matter structures are relatively spared, 
including the corpus callosum, internal capsule, and brain stem, although they are not 
entirely normal. Usually, the cerebellar white matter has a mildly abnormal signal and is 
not swollen (Figure 2.1, A and B) (van der Knaap et al., 1995; Goutieres et al., 1996). 
As the disease progresses, the white matter swelling decreases and cerebral atrophy 
ensues. In general, the subcortical cysts increase in size and number. In some patients, 
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the cysts become very large and occupy a large part of the frontoparietal white matter 
(van der Knaap et al., 1995, Leegwater et al., 2002). 
 
 
 
Fig.2.1 MRI of the brain of a MLC patient (A, B) versus an unaffected child (C, D). The 
transverse T2-weighted image show diffusely abnormal, slightly swollen white matter in the 
patient (A compared with C). The sagittal T1-weight image shows subcortical cysts in the 
anterior-temporal and parietal subcortical region (B compared with D) (adapted from Leegwater 
et al., 2002). 
 
 
Analysis of brain biopsies showed that spongiform white matter changes are related to 
the presence of vacuoles between the outer lamellae of the myelin sheaths, probably 
generated by splitting of these lamellae along the intraperiod line or their incomplete 
compaction (Figure 2.2, A and B) (van der Knaap et al., 1996). According to these 
histopathological findings, the disease can be classified as one of the spongiform 
leukoencephalopathies  
 
                
Fig.2.2 Electron microscopy examination of the brain of a MLC biopsy. (A) Electron 
microscopy image demonstrates numerous membrane covered vacuoles (asterisks) amidst 
several myelinated fibers with well-preserved axons (arrowheads). (B) Detail of a multi-lamellar 
covering of a vacuole (arrow) (adapted from van der Knaap et al., 1996). 
 
Astrogliosis, enlargement of extracellular spaces and alterations in the structure of some 
blood vessels were also reported (Van der Knaap et al., 1996; Pascual-Castroviejo et al., 
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2005). Recently the presence of vacuoles in the end-feet of astrocyte contacting blood-
vessels has been reported (Duarri et al., 2012).  
 
2.3 MLC1 gene and the pathogenetic mutations. 
Based on the pedigree analysis of affected families, the mode of inheritance for the 
MLC disease has been determined to be autosomal recessive. In 2000, by a genome 
wide linkage analysis in 13 affected Turkish families, the locus of the disease gene was 
mapped at the very end of the long arm of chromosome 22 and named MLC1 (Topku et 
al., 2000) and formerly known as KIAA0027. MLC1 spans at least 24 kb genomic DNA 
and contains 11 coding exons and a first non-coding exon, with a start codon in exon 2 
and a 3’untranslated region (UTR) end of 2.2 kb (Figure 2.3). The gene exhibits two 
alternative splice variants (accession numbers NM_015166.2 and NM_139202.1), 
which differ only in their 5‘UTRs (Boor et al., 2006). The transcription start site and the 
promoter region have not yet been fully characterized. 
 
 
 
Fig.2.3 Organization of MLC1 gene. The exons are shown as boxes; introns, as solid lines. The 
gray parts indicate the eight regions that encode transmembrane domains of the protein. The 
positions of the first identified mutations that were found in DNA of patients with MLC are 
shown (indicated) by arrows. Interrupted lines indicate deviations from scale. M = start codon, 
X = stop codon, and fs = frameshift (adapted from Leegwater et al., 2001). 
 
 
 
The MLC1 cDNA was cloned from the immature myeloid cell-line KG-1, and the 
expression in these cells proved to be high in comparison with the expression in a 
variety of human tissues (Nomura et al., 1994). The expression of MLC1 is relatively 
high in the all brain regions examined including cortex, hippocampus, caudate nucleus, 
amygdala, thalamus, and cerebellum (Steinke et al., 2003). It is also expressed in 
peripheral white blood cells and spleen, and the expression in ovary, prostate, placenta, 
thymus, and lung is relatively low (Nomura et al., 1994). In situ hybridization studies 
performed in the mouse and human brain report MLC1 mRNA in glial cells such as 
astrocytes, Bergmann glia and ependymal cells (but not in oligodendrocytes and 
microglia (Schmitt et al., 2003; Teijido et al., 2004; Boor et al., 2005).  
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Almost 75% of MLC patients carry different types of mutations in the MLC1 gene, 
which include formation of stop codons, frameshifts, splice-site mutations, and amino 
acid substitutions of conserved residues  in predicted transmembrane domains or outside 
them (Leegwater et al., 2001; Boor et al., 2005; Teijido et al., 2004; Jeworutzky et al., 
2012), suggesting that alterations of the function of the MLC1 gene product are the 
leading cause of this disease. However, to date no correlation between genotype and 
phenotype has been found. (Patrono et al., 2003; Boor et al., 2006). Interestingly, 
although some patients share the same mutation, they present a wide variability in 
clinical symptoms and disease severity. Some patients have a more severe clinical 
course and never learn to walk, or lose their ability to walk within a few years. In 
contrast, some patients have a milder clinical course and have, even as teenagers, only 
macrocephaly as a symptom. The differences in phenotype between patients carrying 
the same mutations suggest that modifier genes and/or environmental factors have an 
effect in determining the final phenotype. Recently, mutations in the Hepacam/Glialcam 
gene encoding an adhesion-like molecule of unknown function have been found in 
about 60%  of MLC affected patients without mutations in MLC1, indicating the 
genetic heterogeneity of the disease (Jeworutzki et al., 2012; Lòpez-Hernàndez et al., 
2011; Blattner et al., 2003). MLC patients exhist in which no mutations either in MLC1 
and in Hepacam/Glialcam gene have been found (Lòpez-Hernàndez et al., 2011). It is 
possible that in these patients mutations are distribuited in regions of the 
MLC1/Hepacam genes that have not been analysed yet, like the promoter region, the 
non coding exon 1, introns, and the 3’ UTR, all of which may influence the expression 
of the MLC1 gene (Leegwater et al., 2001). 
Even if MLC is a very rare pathology, the disease occurs with relatively high frequency 
in an Asian-Indian tribe and Turkish populations (Singhal et al., 1996; Topçu et al., 
1998). In 1996, Singhal et al described MLC disorder in thirty-one patients from a 
specific Indian community, namely the Agarwals from India: all the patients showed the 
same homozygous mutation (135insC) in exon 2 of the MLC1 gene, suggesting a 
possible founder effect. The same mutation was reported also in another large series 
among Turkish patients (Topçu et al., 1998). There have been reports of similar cases 
from Croatia, Brazil, France and Japan. Overall these data indicate that MLC disease is 
present in several regions of the world, affecting patients of different ethnicities 
(Singhal et al., 2003) and particularly frequent in areas of high levels of consanguinity 
as usually observed for disease with recessive mode of inheritance. 
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2.4 MLC1 protein  
The MLC1 gene encodes for a 377-amino acid protein of still unknown function, 
containing eight putative transmembrane domains and short amino- and carboxylic-
cytoplasmic terminals named MLC1 (Leegwater et al., 2001; Teijido et al., 2004; Boor 
et al., 2005) wich is highly expressed in brain. 
Immunohistochemical studies performed in the mouse and human brain showed that 
MLC1 protein is preferentially expressed in in distal astrocytic processes in perivascular 
and subpial regions, in ependymal cells lining the ventricles and in Bergmann glia, in 
the cerebellum, but not in oligodendrocytes and microglia (Teijido et al., 2004; Boor et 
al., 2005). 
MLC1 shows no similarities with proteins of known function, except for a very low 
homology with a subunit of the voltage-gated potassium (K) channel (Kv1.1) and an 
ABC type of transporter (Meyer et al., 2001; Leegwater et al., 2001). Moreover, MLC1 
contains an internal amino acid repeat that is found in several ion channel proteins 
(Teijido et al., 2004). A search in the Swissprot database indicated that most of the 
human proteins containing eight transmembrane domains have a transporter or channel 
function (Boor et al., 2005). Taken together with the pathological alterations observed 
in MLC patients and the predominant localization of MLC1 in astrocytic processes in 
perivascular, subpial and subependymal regions, these observations suggest that MLC1 
may be involved in astrocyte-mediated processes regulating fluid homeostasis and 
transport of ions or other substances between the central nervous system (CNS) tissue 
and the blood or cerebrospinal fluid. Astrocytes are the most abundant glial cell 
population of the CNS and play an essential role in the maintenance of neural tissue 
homeostasis through the regulation of ions, neurotransmitters and metabolites in the 
extracellular space (Kimelberg, 2010). Recent findings from our and other groups 
indicate that MLC1 interacts with components of the dystrophin–glycoprotein-
associated complex (DGC) (Ambrosini et al., 2008; Boor et al., 2007; Lanciotti et al., 
2010). This multiprotein complex is expressed in brain astrocytes (Waite et al., 2009), 
where it is involved in electrolyte balance and water movement by targeting and 
stabilizing the inwardly rectifying K+ (Kir) channel Kir4.1 and the water channel 
aquaporin-4 (AQP4) at the astrocytic end-foot domains (Neely et al., 2001; Connors et 
al., 2004,). Although it is conceivable that via association with DGC proteins MLC1 
might take part in water and ion homeostasis in the brain, no evidence supporting this 
hypothesis was available since the start of the present research project. 
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Fig.2.4 Predicted MLC1 protein structure. Amino acid position of the different mutations are 
indicated (adapted from Boot et al., 2006). 
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Scope and outline of this thesis 
Megalencephalic leukoencephalopathy with subcortical cysts (MLC, OMIM 604004) is 
a rare congenital and incurable leukodystrophy characterized by early–onset 
macrocephaly, subcortical cysts and swollen appearance of the white matter (van der 
Knaap M.S. et al., 1995). The disease is characterized by ataxia, seizures, degeneration 
of motor functions and late-onset cognitive impairment. MLC patients have a slowly 
progressive clinical course that can be worsened by minor stress, particularly minor 
head trauma and common infections (van der Knaap M.S. et al., 1995; Singhal B.S. et 
al., 2003;   Topku M. et al., 1998). Histopathologically, the brain of MLC patients 
shows intramyelinic vacuole formation, structural alterations of the blood–brain barrier 
and astroglial activation (van der Knaap M.S. et al., 1995; 1996). Enlarged intracellular 
vacuoles localized in the end-feet of vessels contacting astrocytes have also been 
recently described (Duarri A. et al., 2011). 
In the majority of patients (about 75-80%) MLC disease is caused by mutations in a 
single gene (MLC1) encoding a protein highly expressed in CNS astrocytes. However, 
to date no correlation between genotype and phenotype has been found (Leegwater P.A. 
et al., 2001; 2002; Patrono C. et al., 2003; Boor I.P.K. et al., 2006 ). Although MLC1 
function is still unknown, the neuropathological features  observed in MLC patients, in 
particular, swollen white matter, fluid cysts and myelin and astrocyte vacuolation and 
the localization of MLC1 in astrocyte end-feet-contacting brain barriers led to 
hypothesize a role for MLC1 in fluid and ion homeostasis in the central nervous system. 
Thereby, brain damage in MLC patients might be generated by abnormalities in the 
regulation of specific cellular process related to ion and water influx and as a 
consequence in cell volume regulation that in the brain are exerted by astrocytes. Based 
on this evidence the main working hypotheses of this thesis are: i) MLC1 expressed in 
astrocytes plays a key role in ion and fluid homeostasis in the CNS; ii) pathological 
mutations in the MLC1 gene affect MLC1 protein function by altering its intracellular 
distribution and trafficking and modifying molecular interactions that are critical to 
perform the above functions.  
Elucidation of MLC1 protein function represents an essential step to understand MLC 
pathogenesis and provide the rationale basis to develop a therapy for MLC patients.  
To identify MLC1 function  we performed study aimed at investigating the functional 
pathways in which MLC1 is involved in astrocytes.  
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 To this aim we approached the identification of MLC1 molecular interactors as one of 
the most promising strategies to investigate MLC1 functional pathways. 
By applying a panel of  biochemical, immunofluorescence and proteomic techniques on  
primary rat astrocyte cultures and on a new human pathological model generated in our 
laboratory by stably overexpressing MLC1 WT or carrying pathological mutations in 
astrocytoma cells, we have first identified molecular interactors and specific functional 
pathways associated to MLC WT and then we have described mutation specific defects.   
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RESULTS 
 
To shed light on MLC1 function in the brain and in particular in astrocytes where 
MLC1 protein is abundantly expressed, we searched for MLC1 intracellular interactors . 
The identifcation of MLC1 partners is an important step to understand the functional 
patways in wich MLC1 is involved in astrocytes.  
- By using the two-hybrid system assay, we identified the 1 subunit of the Na,K-
ATPase pump, the ubiquitous enzyme responsible for the maintenance of the Na+ and 
K+ gradients across the plasma membrane and cell volume regulation, as an MLC1-
interacting clone. Using biochemical assays as pull-downs, co-fractionation assays and 
immunostainings, we further characterized and confirmed the direct interaction between 
MLC1 and Na,K-ATPase 1 subunit in human and rat astrocytes in vitro and in brain 
tissue. We found that, by binding to Na,K-ATPase, MLC1  takes part to a multiprotein 
complex that includes the inward rectifier potassium channel 4.1 (Kir4.1), the water 
channel aquaporin-4 (AQP-4), the membrane raft associated protein caveolin-1 (cav-1) 
and the dystrophin associated proteins syntrophin (Synt) and dystrobrevin (DB) 
functionally involved in the regulation of cell volume changes occurring after osmotic 
imbalance (Brignone M.S. et al., 2011).  These findings show for the first time the 
direct association of MLC1 with a known protein involved in intracellular osmotic 
control and volume regulation, thus providing new insights into potential mechanisms 
underlying MLC pathogenesis. 
- To elucidate the role of MLC1 in astrocyte physiology and the possible functional 
consequences of MLC1 mutations, we have generated and characterized human 
astrocytoma cell lines overexpressing wild-type (WT) MLC1 and three missense 
mutations described in MLC patients (Lanciotti A. et al., 2012). This work shows that 
distinct pathological mutations differently alter MLC1 intracellular localization and 
interaction with the Na,K-ATPase-associated multiprotein complex in astrocytoma cells 
and affect the response to osmotic changes.  
- Moreover,  it demonstrates that MLC1 functionally interacts with the transient 
receptor potential vanilloid-4 cation channel (TRPV4) to increase intracellular calcium 
influx  in cell subjected to osmotic stress. This calcium influx is essential to regulate the 
rescue of the correct cell volume after hyposmosis induced cell swelling. Conversely, 
mutations hampering MLC1 expression in the plasma membrane fail to activate calcium 
influx leading to abnormal response to osmotic changes  (Lanciotti A. et al., 2012). 
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These findings represent the first evidence that MLC1-induced defects in the 
intracellular calcium response in astrocytes may contribute to the pathogenesis of MLC 
disease.These main results has been object of two publications reported above. 
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HMG-2010-D-00986, Ambrosini 
SUPPLEMENTARY MATERIAL AND METHODS 
Immunofluorescence  
Astrocytes were incubated over night at 4°C with anti-MLC1 pAb (1:50, Atlas AB) and anti-Rab5 
(D-11) mAb (1:25, Santa Cruz Biotecnology) and then for 1 h at RT with a rhodamine-conjugated 
donkey anti-goat (1:100, Jackson, UK) and a fluorescein-conjugated donkey anti-mouse (1:100, 
Jackson, UK) antibody. For double staining with anti-EEA1 mAb (1:50, BD Transduction 
Laboratories) and anti-Kir4.1 pAb (1:50, Alomone), cells were incubated for 1 h at RT. A 
biotinilated secondary antibody (4.3 μg/ml ,Biotin-SP-AffiniPure goat anti-rabbit IgG H+L, Jackson 
Immunoresearch Laboratories) followed by incubation with 2 μg/ml streptavidin-TRITC (Jackson, 
UK) and a fluorescein-conjugated donkey anti-mouse (1:100, Jackson, UK) were used. Coverslips 
were washed, sealed in Vectashield medium (Vector Lab, Burlingame, CA) and analyzed with a 
laser scanning confocal microscope as previously described in Materials and Methods.  
 
Immunohistochemistry of human brain tissue 
Indirect immunofluorescence technique was used to detect MLC1 in post-mortem brain tissues from 
a control patient without neurological disease and from a patient with multiple sclerosis (MS) 
obtained from the UK MS Tissue Bank at Imperial College London. As described in Materials and 
Methods, sections were incubated overnight at 4°C with a mixture of rabbit anti-MLC1 pAb (1:250, 
ATLAS) and anti-Na,K-ATPase ß1 mAb (1:200, Millipore). After extensive washing, sections were 
incubated for 1 h at RT with a mixture of fluorescein-conjugated goat anti-mouse and rhodamine-
conjugated goat anti-rabbit Abs and images were analysed with a fluorescent microscope (Leica 
DM-4000B Microsystems, Bannockburn, IL).  
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Supplementary figures 
 
Figure S1. Characterization of vacuoles induced by 6h hypo-osmotic treatment 
of rat astrocytes. (A) Double immunofluorescence stainings with anti-MLC1 pAb 
(red) and anti-Na,K- β1 mAb (green) show partial colocalization of MLC1 and NaK-
β1 in the membranes bordering the newly formed vacuoles. (B) Double 
immunostainings with anti-MLC1 pAb (red) and anti-EEA1 mAb (green), a marker 
of early endosomes, reveal a partial colocalization of MLC1 and EEA1 around some 
vacuoles (Hypo 6h, arrow) while others are immunopositive only for EEA1 (Hypo 
6h, arrowhead). Scale bars: 20 μm  
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Figure S2. Characterization of vacuoles induced by twelve hours hypo-osmotic 
treatment of rat astrocytes. (A) In astrocytes treated for 12  h with hypo-osmotic 
medium there is a high level of colocalization between MLC1 (red) and Rab5 
(green), a marker of the early endosomes, along the vacuole limiting membranes and 
in the perinuclear area. (B) Staining with anti-Kir4.1 pAb (red) and anti-EEA1 mAb 
(green) shows Kir4.1 and EEA1 colocalization along vacuole membranes. Scale 
bars: 20 μm  
 
 
Figure S3. Immunohistochemical detection of MLC1 in non-pathological 
human brain (A) and in multiple sclerosis (MS)-affected brain (B). (A) 
Immunofluorescence staining of a control human brain section with anti-MLC1 pAb 
shows strong immunoreactivity around blood vessels (asterisks) in the 
periventricular white matter. (B) In the MS brain MLC1 is more abundantly 
expressed in perivascular areas of an active white matter lesion. Numerous small 
blood vessels appeared positive for MLC1. Scale bars: 200 μm 
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SUPPLEMENTARY MATERIALS AND METHODS 
 
Co-purification of His-tagged proteins  
Lysates obtained from two 175 cm
2
 flasks of confluent astrocytoma cell lines stably overexpressing 
histidine-tagged wild-type (WT) and mutated MLC1 (S246R, S280L, C125R) and control cells 
(U251) were incubated overnight at 4 °C with 200 µl (50% v/v suspension) of Ni-NTA Agarose 
(Qiagen, Hilden, Germany). After extensive washings (10 bed volumes of 10 and 25 mM 
Imidazole, 0.2% Triton X-100, 0.15 M NaCl, 20mM Tris-HCl pH 7.4 ), protein elution was carried 
out using imidazole, at a concentration of 50 and 200 mM (Lanciotti A. et al., 2010). The eluted 
proteins were precipitated with acetone (1:4 v/v) and analyzed by SDS-PAGE and WB. 
 
Ouabain-affinity chromatography  
Cells derived from six confluent 175 cm
2
 flasks for each cell line (WT MLC1 and mutated S246R, 
S280L, C125R) untreated and treated for 6 h with hyposmotic solution were incubated with ouabain 
column overnight. Elution was carried out with 2 ml of elution buffer as previously described 
(Brignone M.S. et al., 2011). Obtained samples were precipitated with acetone (1:4 v/v) and 
analysed by SDS-PAGE and WB.  
 
Protein extract preparation and Western blotting  
Astrocytoma cell lines were lysed as described in Materials and Methods. Protein samples were 
subjected to SDS-PAGE using gradient (4–12%) precasted gels (Invitrogen) (Lanciotti A. et al., 
2010), transferred to a nitrocellulose membrane, and immunoblotted overnight at 4 °C with the 
following Abs: anti-MLC1 pAb (1:500, in-house generated), anti-Na,K-ATPase 1 mAb (1 μg/ml, 
Millipore), anti-TRPV4 pAb (1:200, Alomone, Israel), in PBS, 3% BSA. After extensive washings, 
the membrane was incubated for 1 h at RT with horseradish peroxidase-conjugated anti-mouse or 
anti-rabbit Abs (1:10000; Thermo Scientific, Missouri, USA). Immunoreactive bands were 
visualized using an enhanced chemiluminescence reagent (Pierce), according to the manufacturer's 
instructions and exposed on X-ray films. 
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Supplementary figure  
 
 
Figure S1. His co-purification assay to verify Na,K-ATPase β1 association to 
WT or mutated MLC1 in astrocytoma cells. Na,K-ATPase β1 (NaK-β1) was co-
eluted with 50 mM and 200 mM imidazole from Ni-NTA agarose bound with WT 
MLC1 expressing astrocytoma proteins (WT); a decrease in the binding was 
observed in MLC1 S246R and S280L Ni-NTA agarose while no NaK-β1 interacts 
with C125R mutant. Molecular weight markers are indicated on the left (kDa).  
 
 
 
Figure S2. Hyposmotic treatment increases MLC1 association with the Na,K-
ATPase. 
Ouabain-affinity chromatography on astrocytoma cells subjected to hyposmotic 
shock revealed that in astrocytoma cells hyposmotic treatment increased the 
association between MLC1 and the Na,K-ATPase complex in WT and S246R 
expressing cells. No binding between S280L or C125R mutated MLC1 and Na,K-
ATPase was observed. 
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Figure S3.  
 
 
 
 
 
 
 
 
 
Expression of TRPV4 protein in astrocytoma cell lines overexpressing WT 
and pathological MLC1 mutations. WB analysis of protein extracts of 
astrocytoma cells revealed no difference in the expression level of TRPV4 protein 
in control cell line (CTR), wild-type (WT) and mutated MLC1 expressing cells. 
Molecular weight markers are indicated on the left (kDa).  
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Conclusions 
The results obtained in the above papers indicate that MLC1 directly binds the β1 
subunit of Na,K-ATPase and through this interactions it takes part to a multiprotein 
complex that is involved in astrocyte response to osmotic changes. Moreover 
pathological mutations can affect this pathway leading to dysfunctions in astrocyte 
osmoregulatory activity.  
These results are consistent with the starting hypothesis that  brain pathology in patients 
carrying MLC1 mutations may be caused by alterations in the processes regulating 
osmotic balance and cell volume changes. MLC pathological features like fluid cysts, 
myelin vacuolation, enlargement of extracellular space and swelling of the white matter 
(van der Knaap M.S. et al., 1995; Leegwater P.A. et al., 2002; Pascual-Castroviejo I. et 
al., 2005, Duarri A. et al., 2011) are compatible with alterations in astrocyte-mediated 
processes controlling brain volume and ion and fluid exchanges. It is known that 
astrocytes, by contacting neurons and cells lining fluid-filled compartments, play a 
crucial role in regulating ion and water homeostasis through the selective 
transmembrane movements of organic and inorganic molecules and the balance of 
osmotic gradients which involve alterations of cell volume (Sofroniew M.V. and 
Vinters H.V. 2010; Kimelberg H.K. 2010). In astrocytes, Na,K-ATPase is involved in 
cell volume regulation and swelling induced by glutamate and hypo-osmotic treatment 
(Olson J.E. et al., 1986; Lang F. 2007;  Schneider G.H. et al., 1992;  Hansson E. 1994;  
Bender A.S. et al., 1998), water exchange (Illarionova N.B. et al., 2010) and the 
generation of calcium waves (Golovina V. et al., 2003;  Hartford A.K. et al., 2004).  
Although we do not know yet the specific function of MLC1, we hypothesize that this 
protein works as an ion channel itself, or as a chaperone subunit of some other 
channel(s) cooperating with the Na,K-ATPase enzyme in astrocyte swelling and/or 
regulatory volume decrease occurring during hypo-osmotic shock. Exposure of cells to 
hypo-osmotic extracellular fluid leads to water influx, along the osmotic gradient across 
the cell membrane and consequent cell swelling which involves the collaborative 
activity of different transporters, exchangers, water and ion channels, such as  AQPs, 
TRPV4 and Kir4.1. To further investigate MLC1 function in astrocytes and the effect  
of pathological mutations in this project we have generated a human derived 
pathological model based on the stable transfection of  astrocytoma cells with MLC1 wt 
or carrying pathological mutations. 
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The lack of an animal model and the extreme difficulty in obtaining brain biopsies from 
patients have slowed the research in this area and have highlighted the need of new 
pathological models to study MLC mutation-induced brain alterations. Since the 
astrocytoma cell line U251 expressed very low levels of the endogenous protein 
(Ambrosini E. et al., 2008) it represents an appropriate cellular model to analyze the 
effects of the overexpression of MLC1 wild-type or carrying pathological mutations in a 
human astrocytic background. By using this model we found that all the pathological 
missense mutations analysed alter the interaction of MLC1 with the Na,K-ATPase 
multiprotein complex confirming the pathological significance of the MLC1 associate 
molecular pathway revealed in primary astrocytes. Since MLC1 protein is involved in 
the astrocytes response to osmotic changes and hyposmotic shock is known to cause an 
abrupt (osmotic driven) cell swelling due to water movement across plasmalemma, 
followed by regulatory volume decrease (RVD) we have also explored the relationship 
between MLC1 and the calcium-permeable cation channel, TRPV4 that among its 
functions it is known as the cation channel responsible for swelling-induced cytosolic 
calcium increase and for the consequent RVD in response to hyposmosis in different 
type of cells (Becker D. et al., 2005). Recent data obtained in rat astrocytes indicate that 
TRPV4 in cooperation with AQP-4 constitutes the main astroglial osmosensor 
(Benfenati. et al., 2007; 2011) regulating RVD also in hyposmotic astrocytes. Our data 
reveal a role for MLC1 in TRPV4 mediated intracellular calcium influx under 
hyposmosis. Although at present we do not know whether MLC1 binds TRPV4 directly 
or by means of other intermediate proteins, the data obtained by pull-down and ouabain-
chromatography clearly demonstrate that both in primary rat astrocytes and human 
astrocytoma cells MLC1 and TRPV4 interact and participate to the same functional 
multiprotein complex.  Interestingly, in brain the TRPV4 channel is strongly expressed 
in astrocyte end-feet surrounding blood vessels, ependyma and meninges (Benfenati et 
al., 2011), a localization that mimics that of MLC1 and suggests the possibility of their 
interaction in vivo. At the subcellular level TRPV4 has been found in caveolae (Becker 
D. et al., 2005) where also MLC1 and Na,K-ATPase are expressed (Lanciotti A. et al., 
2010; Liu L. et al., 2006; Cai T. et al., 2008). Therefore, it is conceivable that in 
astrocytes MLC1 associated proteins can functionally cooperate in these compartments 
where the activity of mechanosensitive channels is strictly regulated during cell 
swelling (Kozera L. et al., 2009). These findings suggest that defects in intracellular 
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calcium transients in response to osmotic challenges may be involved in the 
pathogenetic mechanism underlying MLC disease. 
Although these data represent a considerable advance in the comprehension of MLC 
pathogenesis, much more work has to be done to fully understand MLC1 function in 
health and MLC disease and exploit this knowledge to develop effective therapies for 
MLC patients. 
For this reason, in this project, we will continue to investigate the functional 
involvement of MLC1 in the cellular pathways associated to already characterized and 
newly discovered MLC1 interactors.  
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Latest results and future perspectives  
Understanding the specific function of MLC1 protein whose mutations are the main 
cause of MLC is an essential step toward identification of disease mechanisms and 
development of effective therapies. Our data strongly indicate MLC1 involvement in 
calcium-mediated mechanisms regulating astrocyte reaction to osmotic stress and 
suggest an ion channel function for MLC1 at plasmamembrane. 
Our latest studies (manuscript under revision) show that MLC1 is also involved in 
regulating ion fluxes in intracellular organelle thus affecting organelle acidity  and, as a 
direct consequence, influencing intracellular protein trafficking. Using human 
astrocytoma cells overexpressing wild-type (WT) or mutated MLC1 we observed that 
WT-MLC1 is abundantly expressed in early and recycling endosomes and that this 
expression is functionally relevant to modulate organelle acidity and the recycling rate 
of MLC1-associated proteins like the TRPV4 channel. Furthermore, although disease-
causing mutations differentially affect MLC1 localization and trafficking, all the 
mutated proteins fail to influence endosomal pH and protein trafficking  through 
endosomal organelles. These findings lead to hypothesize that MLC1, by influencing 
the ion fluxes of endosomal vesicles in which it is expressed may favour its own 
recycling and the recycling of its molecular partners, as observed for TRPV4,  
particularly in stress conditions.  It is also possible that the trafficking of other known 
MLC1 interactors like Na, K-ATPase and associated proteins (Brignone M.S et al., 
2011), V-ATPase or junction proteins (ZO-1, occludin) (Duarri A. et al., 2011) can be 
influenced by MLC1 and defects in the recycling processes of MLC1 and associated 
proteins in conditions of altered brain homeostasis would lead to brain damage observed 
in patients. Interestingly abnormal recycling of junctional proteins can lead to the 
formation of intracellular vacuoles (Dukes J.D. et al., 2011, 2012) similar to those 
observed in the brain of MLC patients (Duarri A. et al., 2011). Moreover endocytosis 
and recycling constitute essential processes in the regulation of the expression of cell 
surface molecules, lipid membrane components like cholesterol and receptors that are 
important in the neural-glial interactions occurring during brain development (Yap C.C. 
and Winckler B., 2012; Shilo B.Z. and Schejter E.D., 2011; Chen J. et al., 2011) . 
Modification of these latter processes may results in disturbances in myelin formation 
as observed for other leukodystrophies in which specific defects in astrocyte maturation 
and functions are responsible for incorrect myelin formation (Bugiani M. et al., 2011; 
Messing A. et al., 2012) 
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Overall our data demonstrate that MLC1 regulates ion fluxes trhough plasmamembrane 
and intracellular organelle thus influencing the recycling of protein involved in 
astrocyte response to stress conditions while MLC1 disease-causing mutations 
deregulate these pathways. 
These data suggest a possible mechanism underlying myelin and extracellular fluid 
abnormalities in the brain of MLC patients and open new unexpected perspective for the 
identification of specific therapeutic strategies for MLC patients.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
70 
 
Reference 
Agre,P., Nielsen,S. and Ottersen,O.P. (2004) Towards a molecular understanding of water 
homeostasis in the brain. Neuroscience, 129(4), 849-50. Review 
Ambrosini,E., Serafini,B., Lanciotti,A., Tosini,F., Scialpi,F., Psaila,R., Di Girolamo,F., 
Petrucci,T.C. and Aloisi,F. (2008) Biochemical characterization of MLC1 protein in 
astrocytes and its association with the dystrophin-glycoprotein complex. Mol. 
Cell.Neurosci., 37, 480-493. 
Amiry-Moghaddam,M. and Ottersen,O.P. (2003)  The molecular basis of water transport in 
the brain. Nat Rev. Neurosci. 4(12), 991-1001. Review. 
Baumann,N. and Pham-Dinh,D. (2001) Biology of oligodendrocyte and myelin in the 
mammalian central nervous system. Physiol. Rev., 81, 871-927. 
Becker,D., Blasé,C., Bereiter-Hahn,J. and Jendrach,M. (2005) TRPV4 exhibits a functional 
role in cell-volume regulation. J. Cell. Sci., 118, 2435-40. 
Bender,A.S., Schousboe,A., Reichelt,W. and Norenberg,M.D. (1998) Ionic mechanisms in 
glutamate-induced astrocyte swelling: role of K+ influx. J. Neurosci. Res., 52, 307-321. 
Benfenati,V., Caprini,M., Dovizio,M., Mylonakou,M.N., Ferroni,S., Ottersen,O.P. and 
Amiry-Moghaddam,M. (2011) An aquaporin-4/transient receptor potential vanilloid 4 
(AQP4/TRPV4) complex is essential for cell-volume control in astrocytes. Proc. Natl. Acad. 
Sci. U S A. 108, 2563-2568. doi: 10.1073/pnas.1012867108.108 
Benfenati,V., Amiry-Moghaddam,M., Caprini,M., Mylonakou,M.N., Rapisarda,C., 
Ottersen,O.P. and Ferroni,S. (2007) Expression and functional characterization of transient 
receptor potential vanilloid-related channel 4 (TRPV4) in rat cortical astrocytes. 
Neuroscience. 148, 876-892. 
Ben-Zeev,B., Levy-Nissenbaum,E., Lahat,H., Anikster,Y., Shinar,Y., Brand,N., Gross-
Tzur,V., MacGregor,D., Sidi,R., Kleta,R., Frydman,M. and Pras,E. (2002) Megalencephalic 
leukoencephalopathy with subcortical cysts; a founder effect in Israeli patients and a higher 
than expected carrier rate among Libyan Jews. Hum. Genet., 111, 214–218. 
Blattner,R., Von Moers,A., Leegwater,P.A., Hanefeld,F.A., van Der Knaap,M.S. and 
Kohler,W. (2003) Clinical and genetic heterogeneity in megalencephalic 
leukoencephalopathy with subcortical cysts (MLC). Neuropediatrics, 34, 215–218. 
Blumkin,L., Mandel,H., Anca-Herschkovitsch,M., Kivity,S., Lev,D. and Lerman-Sagie,T. 
(2009) Familial leukoencephalopathy with slowly progressive dystonia and ataxia. Eur. J. 
Paediatr. Neurol. 13, 530-533.  
Bögler,O., Wren,D., Barnett,S.C., Land,H. and Noble,M. (1990) Cooperation between two 
growth factors promotes extended self-renewal and inhibits differentiation of 
oligodendrocyte-type-2 astrocyte (O-2A) progenitor cells. Proc. Natl. Acad. Sci. U S A., 
87(16), 6368-72. 
Boor,P.K.I, de Groot,K., Mejaski-Bosnjak,V., Brenner,C., van der Knaap,M.S., Scheper,G.C. 
and Pronk,J.C. (2006) Megalencephalic leukoencephalopathy with subcortical cysts: an 
update and extended mutation analysis of MLC1. Hum. Mutat., 27, 505-512. 
Boor,P.K.I., DeGroot,K., Waisfisz,Q., Kamphrost,W., Oudejans,C.B.M., Powers,J.M., 
Pronk,J.C., Shepert,G.C. and Van Der Knaap,M.S. (2005) MLC1 a novel protein in distal 
astroglial processes. J. Neuropathol. Exp. Neurol., 64, 412-419. 
71 
 
Boor,P.K.I., Nagtegaal,M., Kamphorst,W., van der Valk,P., Pronk,J.C., van Horssen,J., 
Dinopoulos,A., Bove,K.E., Pascual-Castroviejo,I., Muntoni,F., et al. (2007) MLC1 is 
associated with the dystrophin-glycoprotein complex at astrocytic endfeet. Acta 
Neuropathol., 114, 403-410. 
Brignone,M.S., Lanciotti,A., Macioce,P., Macchia,G., Gaetani,M., Aloisi,F., Petrucci,T.C., 
and Ambrosini,E. (2011) The beta1 subunit of the na,K-ATPase pump interacts with 
megalencephalic leucoencephalopathy with subcortical cysts protein 1 (MLC1) in brain 
astrocytes: New insights into MLC pathogenesis. Hum Mol Genet., 20, 90-103. doi: 
10.1093/hmg/ddq435. 
Brenner,M., Johnson,A.B., Boespflug-Tanguy,O., Rodriguez,D., Goldman,J.E. and  
Messing,A. (2001) Mutations in GFAP, encoding glial fibrillary acidic protein, are 
associated with Alexander disease. Nat. Genet., 27(1), 117-20. 
Bugiani,M., Boor,I., van Kollenburg,B., Postma,N., Polder,E., van Berkel,C., van 
Kesteren,R.E., Windrem,M.S., Hol,E.M., Scheper,G.C., Goldman,S.A. and van der 
Knaap,M.S. (2011) Defective glial maturation in vanishing white matter disease. J 
Neuropathol. Exp. Neurol., 70, 69-82. doi: 10.1097/NEN.0b013e318203ae74. 
Cai,T., Wang,H., Chen,Y., Liu,L., Gunning,W.T., Quintas,L.E. and Xie,Z.J. (2008) 
Regulation of caveolin-1 membrane trafficking by the Na/K-ATPase. J. Cell Biol., 182, 
1153-1169. 
Campagnoni,A.T. and Skoff,R.P. (2001) The pathobiology of myelin mutants reveal novel 
biological functions of the MBP and PLP genes. Brain. Pathol., 11, 74-91. 
Chen,J., Costa,L.G. and Guizzetti,M. (2011) Assessment of cholesterol homeostasis in 
astrocytes and neurons. Methods Mol. Biol., 758,403-14. doi: 10.1007/978-1-61779-170-
3_27. 
Connors,N.C., Adams,M.E., Froehner,S.C. and Kofuji,P. (2004) The potassium channel 
Kir4.1 associates with the dystrophin-glycoprotein complex via alpha-syntrophin in glia. 
J.Biol. Chem., 279, 28387-28392. 
Del Zoppo,G.J. and Milner,R. (2006) Integrin–matrix interactions in the cerebral 
microvasculature. Arterioscler. Thromb. Vasc. Biol., 26, 1966–1975. 
Del Zoppo,G.J. and Hallenbeck,J.M. (2000) Advances in the vascular pathophysiology of 
ischemic stroke. Thromb. Res. 98(3), 73-81. 
Di Rocco,M., Biancheri,R., Rossi,A., Filocamo,M. and Tortori-Donati,P. (2004) Genetic 
disorders affecting white matter in the pediatric age. Am. J. Med. Genet. B. Neuropsychiatr. 
Genet., 129B, 85-93. 
Duarri,A., de Heredia,M.L., Capdevila-Nortes,X., Ridder,M.C.,Montolio,M., Lopez-
Hernandez,T., Boor,I., Lien,C.F., Hagemann,T., Messing,A. et al (2011) Knockdown of 
MLC1 in primary astrocytes causes cell vacuolation: A MLC disease cell model. Neurobiol 
Dis., 43, 228-238. 
Duarri,A., Teijido,O., López-Hernández,T., Scheper,G.C., Barriere,H., Boor,I., Aguado,F., 
Zorzano,A., Palacín,M., Martínez,A., Lukacs,G.L., van der Knaap,M.S., Nunes,V. and 
Estévez,R. (2008) Molecular pathogenesis of megalencephalic leukoencephalopathy with 
subcortical cysts: mutations in MLC1 cause folding defects. Hum. Mol.Genet., 17, 3728–
3739. 
72 
 
Dukes,J.D., Whitley,P. and Chalmers A.D. (2012) The PIKfyve inhibitor YM201636 blocks 
the continuous recycling of the tight junction proteins claudin-1 and claudin-2 in MDCK 
cells. PLoS One, 7(3),e28659. doi: 10.1371/journal.pone.0028659. 
Dukes,J.D., Fish,L., Richardson,J.D., Blaikley,E., Burns,S., Caunt,C.J., Chalmers,A.D. and  
Whitley,P. (2011) Functional ESCRT machinery is required for constitutive recycling of 
claudin-1 and maintenance of polarity in vertebrate epithelial cells. Mol. Biol. Cell., 
22,3192-205. doi: 10.1091/mbc.E11-04-0343. 
Dreyfus,C.F., Dai,X., Lercher,L.D., Racey,B.R., Friedman,W.J. and Black,I.B. (1999) 
Expression of neurotrophins in the adult spinal cord in vivo. J. Neurosci. Res., 56(1), 1-7. 
Faissner,A., Pyka,M., Geissler,M., Sobik,T., Frischknecht,R., Gundelfinger,E.D. and 
Seidenbecher,C. (2010) Contributions of astrocytes to synapse formation and maturation - 
Potential functions of the perisynaptic extracellular matrix. Brain Res. Rev., 63, 26-38.  
Giaume,C., Koulakoff,A., Roux,L., Holcman,D. and Rouach,N. (2010) Astroglial networks: a 
step further in neuroglial and gliovascular interactions. Neuroscience, 11, 87-99 
Golovina,V., Song,H., James,P., Lingrel,J. and Blaustein,M. (2003) Regulation of Ca2+ 
signaling by Na+ pump alpha-2 subunit expression. Ann. N. Y. Acad. Sci., 986, 509-513.  
Goutieres,F., Boulloche,J., Bourgeois,M. and Aicardi,J. (1996) Leukoencephalopathy, 
megalencephaly, and mild clinical course. A recently individualized familial 
leukodystrophy. Report on five new cases. J. Child Neurol., 11, 439–444. 
Hansson,E. (1994) Metabotropic glutamate receptor activation induces astroglial swelling. 
J.Biol. Chem., 269, 21955-21961. 
Huang,Y.H., Sinha,S.R., Tanaka,K., Rothstein,J.D. and Bergles,D.E. (2004) Astrocyte 
glutamate transporters regulate metabotropic glutamate receptor-mediated excitation of 
hippocampal interneurons. J. Neurosci. 24(19), 4551-9. 
Hartford,A.K., Messer,M.L., Moseley,A.E., Lingrel,J.B. and Delamere,N.A. (2004) 
Na,KATPase alpha 2 inhibition alters calcium responses in optic nerve astrocytes. Glia, 45, 
229-237. 
Illarionova,N.B., Gunnarson,E., Li,Y., Brismar,H., Bondar,A., Zelenin,S. and Aperia,A. 
(2010) Functional and molecular interactions between aquaporins and Na,K-ATPase. 
Neuroscience, 168, 915-925. 
Jeworutzki,E., López-Hernández,T., Capdevila-Nortes,X., Sirisi,S., Bengtsson,L., 
Montolio,M., Zifarelli,G., Arnedo,T., Müller,C.S., Schulte,U., Nunes,V., Martínez,A., 
Jentsch,T.J., Gasull,X., Pusch,M. and Estévez,R. (2012) GlialCAM, a protein defective in a 
leukodystrophy, serves as a ClC-2 Cl(-) channel auxiliary subunit. Neuron, 73, 951-61. doi: 
0.1016/j.neuron.2011.12.039. 
Kaye,E.M. (2001) Update on genetic disorders affecting white matter. Pediatr. Neurol., 24, 
11-24.  
Kandel E.R., Schwartz J.H., and Jessell T.M., Principles of Neural Science, Fourth ed. 
(McGraw-Hill, 2000). 
Kimelberg HK and Nedergaard M. (2010) Functions of astrocytes and their potential as 
therapeutic targets. Neurotherapeutics., 4, 338-53. doi: 10.1016/j.nurt.2010.07.006. 
Kimelberg,H.K. (2010) Functions of mature mammalian astrocytes: a current view. 
Neuroscientist., 16, 79-106. 
73 
 
Kristjánsdóttir,R., Uvebrant,P. and Wiklund,L.M. (2000) Clinical characteristics of children 
with cerebral white matter abnormalities. Eur. J. Paediatr. Neurol., 4, 17-26. 
Lanciotti,A., Brignone,M.S., Molinari,P., Visentin,S., De Nuccio,C., Macchia,G., Aiello,C., 
Bertini,E., Aloisi,F., Petrucci,T.C. and Ambrosini,E. (2012) Megalencephalic 
leukoencephalopathy with subcortical cysts protein 1 functionally cooperates with the 
TRPV4 cation channel to activate the response of astrocytes to osmotic stress: dysregulation 
by pathological mutations. Hum. Mol. Genet., 21, 2166-80. doi: 10.1093/hmg/dds032. 
Lanciotti,A., Brignone,M.S., Camerini,S., Serafini,B., Macchia,G., Raggi,C., Molinari,P., 
Crescenzi,M., Musumeci,M., Sargiacomo,M., et al. (2010) MLC1 trafficking and membrane 
expression in astrocytes: role of caveolin-1 and phosphorylation. Neurobiol. Dis., 37, 581-
595. 
Lang,F. (2007) Mechanisms and significance of cell volume regulation. J. Am. Coll. Nutr., 26, 
613S-623S. 
Lappe-Siefke,C., Goebbels,S., Gravel,M., Nicksch,E., Lee,J., Braun,P.E., Griffiths,I.R. and 
Nave,K.A. (2003) Disruption of Cnp1 uncouples oligodendroglial functions in axonal 
support and myelination. Nat.Genet., 33, 366-374. 
Leegwater,P.A., Boor,P.K., Yuan,B.Q., van der Steen,J., Visser,A., Konst,A.A., 
Oudejans,C.B., Schutgens,R.B., Pronk,J.C. and van der Knaap,M.S. (2002) Identification of 
novel mutations in MLC1 responsible for megalencephalic leukoencephalopathy with 
subcortical cysts. Hum. Genet., 110, 279–283. 
Leegwater,P.A., Yuan,B.Q., Van Der Steen,J., Mulders,J., Konst,A.A., Boor,P.K., Mejaski-
Bosnjak,V., Van Der Maarel,S.M., Frants,R.R., Oudejans,C.B., et al. (2001) Mutations of 
MLC1 (KIAA0027), encoding a putative membrane protein, cause megalencephalic 
leukoencephalopathy with subcortical cysts. Am. J. Hum. Genet., 68, 831-838. 
Li,G., Yuan,W. and Fu,B.M. (2010) A model for the blood-brain barrier permeability to water 
and small solutes. J. Biomech., 43(11), 2133-40. doi: 10.1016/j.jbiomech.2010.03.047. 
López-Hernández,T., Ridder,M.C., Montolio,M., Capdevila-Nortes,X., Polder,E., Sirisi,S., 
Duarri,A., Schulte,U., Fakler,B., Nunes,V., Scheper,G.C., Martínez,A., Estévez,R. and van 
der Knaap,M.S. (2011) Mutant GlialCAM causes megalencephalic leukoencephalopathy 
with subcortical cysts, benign familial macrocephaly, and macrocephaly with retardation 
and autism. Am. J. Hum. Genet., 88, 422-32. doi: 10.1016/j.ajhg.2011.02.009. 
Ludwin,S.K. (1997) The pathobiology of the oligodendrocyte. J. Neuropathol. Exp. Neurol., 
56, 111–124 
Luzi,P., Abraham,R.M., Rafi,M.A., Curtis,M., Hooper,D.C. and Wenger,D.A. (2009) Effects 
of treatments on inflammatory and apoptotic markers in the CNS of mice with globoid cell 
leukodystrophy. Brain Res. 1300, 146-58. doi: 10.1016/j. 
Mack,A.F. and Wolburg,H. (2012) A Novel Look at Astrocytes: Aquaporins, Ionic 
Homeostasis, and the Role of the Microenvironment for Regeneration in the CNS. 
Neuroscientist. May 29. [Epub ahead of print] 
Magistretti,P.J., Sorg, O., Yu,N., Martin,J.L. and Pellerin,L. (1993) Neurotransmitters 
regulate energy metabolism in astrocytes: implications for the metabolic trafficking between 
neural cells. Dev. Neurosci., 15, 306–312. 
Messing,A., Brenner,M., Feany,M.B., Nedergaard,M. and Goldman,J.E. (2012) Alexander 
disease. J. Neurosci., 32, 5017-23. doi: 10.1523/JNEUROSCI.5384-11.2012. 
74 
 
Meyer,J., Huberth,A., Ortega,G., Syagailo,Y.V., Jatzke,S., Mossner,R., Strom,T.M., 
Ulzheimer-Teuber,I., Stober,G., Schmitt,A. and Lesch,K.P. (2001). A missense mutation in 
a novel gene encoding a putative cation channel is associated with catatonic schizophrenia in 
a large pedigree. Mol. Psychiatry, 6, 302–306. 
Morell, P. Myelin, Second ed. (Plenum, New York, 1984). 
Nagelhus,E.A., Mathiisen,T.M. and Ottersen,O.P. (2004) Aquaporin-4 in the central nervous 
system: cellular and subcellular distribution and coexpression with KIR4.1. Neuroscience. 
129(4), 905-13. 
Neely,J.D., Amiry-Moghaddam,M., Ottersen,O.P., Froehner,S.C., Agre,P. and Adams,M.E. 
(2001) Syntrophin-dependent expression and localization of Aquaporin-4 water channel 
protein. Proc. Natl. Acad. Sci. U. S. A., 98, 14108-14113 
Noble,M. and Murray,K (1984). Purified astrocytes promote the in vitro division of a 
bipotential glial progenitor cell. EMBO J., 3(10), 2243-7. 
Noble,M., Murray ,K., Stroobant,P., Waterfield,M.D. and Riddle,P. (1988) Platelet-derived 
growth factor promotes division and motility and inhibits premature differentiation of the 
oligodendrocyte/type-2 astrocyte progenitor cell. Nature., 333(6173), 560-2. 
Nomura,N., Miyajima,N., Sazuka,T., Tanaka,A., Kawarabayasi,Y.,Sato, S., Nagase,T., 
Seki,N., Ishikawa,K. and Tabata,S. (1994) Prediction of the coding sequences of 
unidentified human genes: I. The coding sequences of 40 new genes (KIAA0001–
KIAA0040) deduced by analysis of randomly sampled cDNA clones from human immature 
myeloid cell line KG-1 (supplement). DNA Res., 1, 47–56. 
Olson,J.E., Sankar,R., Holtzman,D., James,A. and Fleischhacker,D. (1986) Energydependent 
volume regulation in primary cultured cerebral astrocytes. J. Cell. Physiol., 128, 209-215. 
Pascual-Castroviejo,I., Van der Knaap,M.S., Pronk,J.C., Garcia-Segura,J.M., Gutierez-
Molina,M. and Pascual-Pascual,S.I. (2005) Vacuolating megalencephalic 
leukoencephalopathy: 24 year follow-up of two siblings. Neurologia, 20, 33-40. 
Patrono,C., Di Giacinto,G., Eymard-Pierre,E., Santorelli,F.M., Rodriguez,D., De Stefano,N., 
Federico,A., Gatti,R., Benigno,V., Megarbané,A., et al (2003) Genetic heterogeneity of 
megalencephalic leukoencephalopathy and subcortical cysts. Neurology, 61, 534-537. 
PellerinPellerin,L. and Magistretti,P.J. (1994) Glutamate uptake into astrocytes stimulates 
aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proc. 
Natl. Acad. Sci. U.S.A., 91, 10625–10629. 
Quarles,R.H. (2002) Myelin sheaths: glycoproteins involved in their formation, maintenance 
and degeneration. Cell. Mol.Life Sci., 59, 1851-1871. 
Ransom B., Behar T., and Nedergaard M., Trends Neurosci 26 (10), 520 (2003). 
Richardson,W.D., Pringle,N., Mosley,M.J., Westermark,B. and Dubois-Dalcq,M. (1988) A 
role for platelet-derived growth factor in normal gliogenesis in the central nervous system. 
Cell., 53(2), 309-19. 
Ridder,M.C., Boor,I., Lodder,J.C., Postma,N.L., Capdevila-Nortes,X., Duarri,A., 
Brussaard,A.B., Estévez,R., Scheper,G.C., Mansvelder,H.D. and van der Knaap,M.S. (2011) 
Megalencephalic leucoencephalopathy with cysts: defect in chloride currents and cell 
volume regulation. Brain, 134,3342-3354. 
75 
 
Schmitt,A., Gofferje,V., Weber,M., Meyer,J., Mossner,R. and Lesch,K.P. (2003) The brain-
specific protein MLC1 implicated in megalencephalic leukoencephalopathy with subcortical 
cysts is expressed in glial cells in the murine brain. Glia, 44, 283–295. 
Schneider,G.H., Baethmann,A. and Kempski,O. (1992) Mechanisms of glial swelling induced 
by glutamate. Can. J. Physiol. Pharmacol., 70, 334-343. 
Schwartz,J.P., Taniwaki,T., Messing,A. and Brenner,M. (1996) Somatostatin as a trophic 
factor. Analysis of transgenic mice overexpressing somatostatin in astrocytes. Ann. N .Y. 
Acad. Sci., 780, 29-35. 
Sherman,D.L. and Brophy,P.J. (2005) Mechanisms of axon ensheathment and myelin growth. 
Nat. Rev. Neurosci.,6, 683-690.  
Shilo,B.Z. and Schejter,E.D. (2011) Regulation of developmental intercellular signalling by 
intracellular trafficking. EMBO J., 30,3516-26. doi: 10.1038/emboj.2011.269. Review. 
Singhal,B.S., Gorospe,J.R. and Naidu,S. (2003) Megalencephalic leukoencephalopathy with 
subcortical cysts. J. Child Neurol., 18, 646-652. 
Singhal,B.S., Gursahani,R.D., Udani,V.P. and Biniwale,A.A. (1996) Megalencephalic 
leukodystrophy in an Asian Indian ethnic group. Pediatr. Neurol., 14, 291–296. 
Sofroniew,M.V. and Vinters,H.V. (2010) Astrocytes: biology and pathology. Acta 
Neuropathol., 119, 7-35. 
Spassky N., Merkle F. T., Flames N. et al., (2005).J Neurosci 25 (1), 10  
Steinke,V., Meyer,J., Syagailo,Y.V., Ortega,G., Hameister,H., Mossner,R., Schmitt,A. and 
Lesch,K.P. (2003). The genomic organization of the murine Mlc1 (Wkl1, KIAA0027) gene. 
J. Neural. Transm., 110, 333–343. 
Strange,K., Emma,F. and Jackson,P.S. (1996) Cellular and molecular physiology of volume-
sensitive anion channels. Am. J. Physiol., 270(3 Pt 1), C711-30. Review. 
Teijido,O., Casaroli-Marano,R., Kharkovets,T., Aguado,F., Zorzano,A., Palacín,M., 
Soriano,E., Martínez,A. and Estévez,R. (2007) Expression patterns of MLC1 protein in the 
central and peripheral nervous systems. Neurobiol. Dis., 26, 532–545. 
Teijido,O., Martinez,A., Pusch,M., Zorzano,A., Soriano,E., Del Rio,J.A., Palacin,M. and 
Estevez,R. (2004) Localization and functional analyses of the MLC1 protein involved in 
megalencephalic leukoencephalopathy with subcortical cysts. Hum. Mol. Genet., 13, 2581-
2594. 
Theis,M. and Giaume,C. (2012) Connexin-based intercellular communication and astrocyte 
heterogeneity. Brain Res., 3, 1487:88-98. doi: 10.1016/j. 
TopKu,M., Saatci,I., Topcuoglu,M.A., et al. (1998) Megalencephaly and leukodystrophy with 
mild clinical course: a report on 12 new cases. Brain Dev., 20:142–153. 
Topku,M., Gartioux,C., Ribierre,F., Yalçinkaya,C., Tokus,E., Oztekin,N., Beckmann,J.S., 
Ozguc,M. and Seboun,E. (2000) Vacuolating megalencephalicleukoencephalopathy with 
subcortical cysts mapped to chromosome 22qtel. Am. J. Hum. Genet., 66, 733-739. 
Tress,O., Maglione,M., Zlomuzica,A., May,D., Dicke,N., Degen,J., Dere,E.,  Kettenmann,H., 
Hartmann,D. and Willecke,K. (2011) Pathologic and phenotypic alterations in a mouse 
expressing a connexin47 missense mutation that causes Pelizaeus-Merzbacher-like disease 
in humans. PLoS Genet., 7, e1002146. doi: 10.1371/journal.pgen.1002146. 
van der Knaap,M. S. and Valk, J. (2005) Magnetic Resonance of Myelination and Myelin 
Disorders, Third ed. (Springer, Heidelberg,). 
76 
 
van der Knaap,M.S., Boor,I.P.K. and Estévez,R. (2012) Megalencephalic 
leukoencephalopathy with subcortical cysts: chronic white matter oedema due to a defect in 
brain ion and water homoeostasis. Lancet. Neurol., 11,973-85. doi: 10.1016/S1474-
4422(12)70192-8. 
van der Knaap,M.S. (2001) Magnetic resonance in childhood white-matter disorders. Dev. 
Med. Child. Neurol., 43, 705-712. 
van der Knaap,M.S., Barth,P.G., Vrensen,G.F. and Valk,J. (1996) Histopathology of an 
infantile-onset spongiform leukoencephalopathy with a discrepantly mild clinical course. 
Acta Neuropathol., 92, 206–212. 
van der Knaap,M.S., Smit,L.M. and Bart,P.G. (1997) Magnetic resonance imaging in 
classification of congenital muscular dystrophies with brain abnormalities. Ann. Neurol., 42, 
50–59. 
van der Knaap,M.S., Valk,J., Barth,P.G., Smit,L.M., van Engelen,B.G. and Tortori Donati,P. 
(1995) Leukoencephalopathy with swelling in children and adolescents: MRI patterns and 
differential diagnosis. Neuroradiology., 37, 679-686. 
Voutsinos-Porche,B., Bonvento,G., Tanaka,K., Steiner,P., Welker,E., Chatton,J.Y., 
Magistretti,P.J. and Pellerin,L. (2003) Glial glutamate transporters mediate a functional 
metabolic crosstalk between neurons and astrocytes in the mouse developing cortex. 
Neuron, 37, 275–286. 
Wanga,D.D. and Bordey,A. (2008) The astrocyte odyssey. Progress in Neurobiology, 86, 
342–367. 
Yap,C.C. and Winckler,B. (2012) Harnessing the power of the endosome to regulate neural 
development. Neuron, 74, 440-51. doi: 10.1016/j.neuron.2012.04.015. Review. 
Zorec,R., Araque,A., Carmignoto,G., Haydon,P.G., Verkhratsky,A. and Parpura,V. (2012) 
Astroglial excitability and gliotransmission: an appraisal of Ca2+ as a signalling route. ASN 
Neuro. 4(2). doi:pii: e00080. 10.1042/AN20110061. Review. 
